Cell Source, Inc. announced that it is planning to commence a Phase I/II clinical trial with a cell therapy treatment that aspires to significantly reduce the need for immune suppression treatment for both donor-matched and "mismatched" bone marrow transplant patients. This treatment could potentially lead to a substantial increase in patient survival rates.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0008 USD | +300.00% | +300.00% | -99.83% |
1st Jan change | Capi. | |
---|---|---|
-99.83% | 32.82K | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- CLCS Stock
- News Cell Source, Inc.
- Cell Source, Inc. to Commence a Phase I/II Clinical Trial with a Cell Therapy Treatment